Clear direction for hospitalized pneumonia patients

FDA-cleared Unyvero LRT lower respiratory tract infection panel helps you quickly optimize antibiotic therapy.

Detects the largest number of relevant pathogens and resistance markers*

Delivers rapid, reliable, and actionable answers

Enables earlier diagnosis and selection of optimal treatment

Unyvero LRT uniquely detects a total of 29 clinically relevant bacterial pathogens and resistance markers, including the broadest carbapenemase resistance coverage.*

For clear, comprehensive, and reliable results to advance antimicrobial stewardship initiatives, Unyvero points the way.

* Compared to other molecular panels.

The Unyvero Solution


Actionable results in under five hours


29 targets in one test (19 bacteria and 10 resistance markers)


Sample-to-answer, easy workflow


92.5% sensitivity, 97.4% specificity

What can Unyvero mean to you?

Microbiology Laboratories

Need to identify the pathogen and resistance quickly.

Infectious Disease

Need to know the cause to implement the right treatment plan.

Antibiotic Stewardship

Need to prescribe appropriate antibiotics for effective treatment.

Hospital Administration

Need to control healthcare costs, increase DRG yield and improve ROI.

Clinical Evidence

Recent external studies show the Unyvero LRT results are actionable:

Evaluation of a Rapid Highly Multiplexed Molecular Diagnostic Lower Respiratory Tract Panel for Use with Bronchoalveolar Lavage Specimens (Beaumont Hospital)
ASM Microbe 2019

June 22, 2019

Use of a Multiplex PCR Pneumonia Panel for the Microbial Analysis of Lower Respiratory Tract Specimens from Children (Children’s National Medical Center)
ASM Microbe 2019

June 22, 2019

Comparison of a Multiplex PCR Lower Respiratory Tract Assay with Bacterial Culture (UNC School of Medicine)
CVS 2018

May 07, 2018

Want to know more?